Team:Heidelberg/Project/miRNA Kit
From 2010.igem.org
Laura Nadine (Talk | contribs) (→Introduction) |
Laura Nadine (Talk | contribs) (→Introduction) |
||
Line 25: | Line 25: | ||
With our Synthetic miRNA Kit we can make not only make use of the miRNA properties mentioned above; additionally, a big part of our project aims at the characterization of binding site sequences. Some functionally important parts of miRNAs have been described in literature, such as the seed region. The seed region is defined as a region of seven nucleotides that show perfect pairing between the miRNA and its target sequence. The seed usually consists of the nucleotides 2-8 of a miRNA binding sites (Grimson et al., 2007; Bartel, 2009). Based on this simple principle, we randomized our miRNA binding sites between nucleotide 9 and 12 or 9 and 22 or tried rational exchanges of nucleotides to see how they would effect binding of the miRNA, e. g. replacing one purin base with another versus replacing it with a pyrimidin base. A more detail description of the different binding sites we characterized can be found in our [https://2010.igem.org/Team:Heidelberg/Project/miMeasure measurements] page. After creating a binding site library and testing the miRNA-binding site interaction in vitro, we were able to compute an in [https://2010.igem.org/Team:Heidelberg/Modeling/miGUI silico model] based on a machine learning approach. | With our Synthetic miRNA Kit we can make not only make use of the miRNA properties mentioned above; additionally, a big part of our project aims at the characterization of binding site sequences. Some functionally important parts of miRNAs have been described in literature, such as the seed region. The seed region is defined as a region of seven nucleotides that show perfect pairing between the miRNA and its target sequence. The seed usually consists of the nucleotides 2-8 of a miRNA binding sites (Grimson et al., 2007; Bartel, 2009). Based on this simple principle, we randomized our miRNA binding sites between nucleotide 9 and 12 or 9 and 22 or tried rational exchanges of nucleotides to see how they would effect binding of the miRNA, e. g. replacing one purin base with another versus replacing it with a pyrimidin base. A more detail description of the different binding sites we characterized can be found in our [https://2010.igem.org/Team:Heidelberg/Project/miMeasure measurements] page. After creating a binding site library and testing the miRNA-binding site interaction in vitro, we were able to compute an in [https://2010.igem.org/Team:Heidelberg/Modeling/miGUI silico model] based on a machine learning approach. | ||
- | The basic set-up of our fine tuning construct, miTuner, allows on the simultaneous expression of a synthetic miRNA and a gene of interest (GOI) that is fused with a binding site for this miRNA. Our kit comes with different parts that can be combined by choice, e. g. different mammalian promoters and characterized binding sites of specific properties. By chosing a certain binding site to tag the GOI, one can adjust the level of expression of this gene. In a proof of principle approach, we show the fine tuning capability of our set up using a [https://2010.igem.org/Team:Heidelberg/Notebook/Material_Methods#Dual_Luciferase_Assay Dual Luciferase Assay]. Here, firefly luciferase acts as the GOI targeted by a synthetic miRNA, while Renilla is used to normalize measurements. | + | The basic set-up of our fine tuning construct, miTuner, allows on the simultaneous expression of a synthetic miRNA and a gene of interest (GOI) that is fused with a binding site for this miRNA. Our kit comes with different parts that can be combined by choice, e. g. different mammalian promoters and characterized binding sites of specific properties. By chosing a certain binding site to tag the GOI, one can adjust the level of expression of this gene. In a proof of principle approach, we show the fine tuning capability of our set up using a [https://2010.igem.org/Team:Heidelberg/Notebook/Material_Methods#Dual_Luciferase_Assay Dual Luciferase Assay]. Here, firefly luciferase acts as the GOI targeted by a synthetic miRNA, while Renilla is used to normalize measurements. FIGURES |
- | We further tested our kit using a gene that is an interesting candidate for gene therapy, human alpha-1-antitrypsin (haat) (ref, description). In this approach, we tag haat as our GOI with binding sites that we measured and characterized with our [https://2010.igem.org/Team:Heidelberg/Project/miMeasure miMeasure] construct beforehand and wanted to test in a gene therapeutic background. | + | We further tested our kit using a gene that is an interesting candidate for gene therapy, human alpha-1-antitrypsin (haat) (ref, description). In this approach, we tag haat, that we used as our GOI, with binding sites that we measured and characterized with our [https://2010.igem.org/Team:Heidelberg/Project/miMeasure miMeasure] construct beforehand and wanted to test in a gene therapeutic background. |
==Results== | ==Results== |
Revision as of 19:25, 24 October 2010
|
|
|||